TrialBritish journal of cancer2016

Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.

Martin H Voss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.